[1]
|
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
DOI=10.1016/0092-8674(91)90410-Z; PubMed=1849461 [NCBI, ExPASy, EBI, Israel, Japan]
Skolnik E.Y.,
Margolis B.,
Mohammadi M.,
Lowenstein E.,
Fischer R.,
Drepps A.,
Ullrich A.,
Schlessinger J.;
"Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases.";
Cell 65:83-90(1991).
|
[2]
|
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 4), INTERACTION WITH IRS1, AND TISSUE SPECIFICITY.
TISSUE=Skeletal muscle;
PubMed=8628286 [NCBI, ExPASy, EBI, Israel, Japan]
Antonetti D.A.,
Algenstaedt P.,
Kahn C.R.;
"Insulin receptor substrate 1 binds two novel splice variants of the regulatory subunit of phosphatidylinositol 3-kinase in muscle and brain.";
Mol. Cell. Biol. 16:2195-2203(1996).
|
[3]
|
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
TISSUE=Skeletal muscle;
Udelhoven M.,
Kotzka J.,
Knebel B.,
Klein E.,
Krone W.,
Mueller-Wieland D.;
Submitted (JUN-2000) to the EMBL/GenBank/DDBJ databases.
|
[4]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT ILE-326.
TISSUE=Brain;
Totoki Y.,
Toyoda A.,
Takeda T.,
Sakaki Y.,
Tanaka A.,
Yokoyama S.;
Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
|
[5]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2), AND VARIANT LYS-451.
TISSUE=Placenta, and Skeletal muscle;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
|
[6]
|
INTERACTION WITH INSR.
PubMed=8276809 [NCBI, ExPASy, EBI, Israel, Japan]
Van Horn D.J.,
Myers M.G. Jr.,
Backer J.M.;
"Direct activation of the phosphatidylinositol 3'-kinase by the insulin receptor.";
J. Biol. Chem. 269:29-32(1994).
|
[7]
|
INTERACTION WITH IGF1R.
DOI=10.1074/jbc.270.26.15639; PubMed=7541045 [NCBI, ExPASy, EBI, Israel, Japan]
Craparo A.,
O'Neill T.J.,
Gustafson T.A.;
"Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor.";
J. Biol. Chem. 270:15639-15643(1995).
|
[8]
|
INTERACTION WITH INSR.
PubMed=7537849 [NCBI, ExPASy, EBI, Israel, Japan]
Gustafson T.A.,
He W.,
Craparo A.,
Schaub C.D.,
O'Neill T.J.;
"Phosphotyrosine-dependent interaction of SHC and insulin receptor substrate 1 with the NPEY motif of the insulin receptor via a novel non-SH2 domain.";
Mol. Cell. Biol. 15:2500-2508(1995).
|
[9]
|
INTERACTION WITH LAT.
DOI=10.1016/S0092-8674(00)80901-0; PubMed=9489702 [NCBI, ExPASy, EBI, Israel, Japan]
Zhang W.,
Sloan-Lancaster J.,
Kitchen J.,
Trible R.P.,
Samelson L.E.;
"LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation.";
Cell 92:83-92(1998).
|
[10]
|
INTERACTION WITH IRS4.
DOI=10.1074/jbc.273.17.10726; PubMed=9553137 [NCBI, ExPASy, EBI, Israel, Japan]
Fantin V.R.,
Sparling J.D.,
Slot J.W.,
Keller S.R.,
Lienhard G.E.,
Lavan B.E.;
"Characterization of insulin receptor substrate 4 in human embryonic kidney 293 cells.";
J. Biol. Chem. 273:10726-10732(1998).
|
[11]
|
INTERACTION WITH TRAT1.
DOI=10.1084/jem.188.3.561; PubMed=9687533 [NCBI, ExPASy, EBI, Israel, Japan]
Bruyns E.,
Marie-Cardine A.,
Kirchgessner H.,
Sagolla K.,
Shevchenko A.,
Mann M.,
Autschbach F.,
Bensussan A.,
Meuer S.,
Schraven B.;
"T cell receptor (TCR) interacting molecule (TRIM), a novel disulfide-linked dimer associated with the TCR-CD3-zeta complex, recruits intracellular signaling proteins to the plasma membrane.";
J. Exp. Med. 188:561-575(1998).
|
[12]
|
INTERACTION WITH HCST.
PubMed=10528161 [NCBI, ExPASy, EBI, Israel, Japan]
Chang C.,
Dietrich J.,
Harpur A.G.,
Lindquist J.A.,
Haude A.,
Loke Y.W.,
King A.,
Colonna M.,
Trowsdale J.,
Wilson M.J.;
"KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties.";
J. Immunol. 163:4651-4654(1999).
|
[13]
|
INTERACTION WITH CBLB.
DOI=10.1038/sj.onc.1202499; PubMed=10086340 [NCBI, ExPASy, EBI, Israel, Japan]
Ettenberg S.A.,
Keane M.M.,
Nau M.M.,
Frankel M.,
Wang L.-M.,
Pierce J.H.,
Lipkowitz S.;
"cbl-b inhibits epidermal growth factor receptor signaling.";
Oncogene 18:1855-1866(1999).
|
[14]
|
INTERACTION WITH CBLB, AND UBIQUITINATION.
DOI=10.1074/jbc.M008901200; PubMed=11087752 [NCBI, ExPASy, EBI, Israel, Japan]
Fang D.,
Wang H.-Y.,
Fang N.,
Altman Y.,
Elly C.,
Liu Y.-C.;
"Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells.";
J. Biol. Chem. 276:4872-4878(2001).
|
[15]
|
INTERACTION WITH CD3Z AND CD28, AND UBIQUITINATION.
DOI=10.1038/ni0901-870; PubMed=11526404 [NCBI, ExPASy, EBI, Israel, Japan]
Fang D.,
Liu Y.-C.;
"Proteolysis-independent regulation of PI3K by Cbl-b-mediated ubiquitination in T cells.";
Nat. Immunol. 2:870-875(2001).
|
[16]
|
INTERACTION WITH NISCH.
DOI=10.1074/jbc.M111838200; PubMed=11912194 [NCBI, ExPASy, EBI, Israel, Japan]
Sano H.,
Liu S.C.H.,
Lane W.S.,
Piletz J.E.,
Lienhard G.E.;
"Insulin receptor substrate 4 associates with the protein IRAS.";
J. Biol. Chem. 277:19439-19447(2002).
|
[17]
|
INTERACTION WITH LAX1.
DOI=10.1074/jbc.M208946200; PubMed=12359715 [NCBI, ExPASy, EBI, Israel, Japan]
Zhu M.,
Janssen E.,
Leung K.,
Zhang W.;
"Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling.";
J. Biol. Chem. 277:46151-46158(2002).
|
[18]
|
INTERACTION WITH HIV-1 NEF.
DOI=10.1006/viro.2002.1365; PubMed=12009866 [NCBI, ExPASy, EBI, Israel, Japan]
Linnemann T.,
Zheng Y.-H.,
Mandic R.,
Peterlin B.M.;
"Interaction between Nef and phosphatidylinositol-3-kinase leads to activation of p21-activated kinase and increased production of HIV.";
Virology 294:246-255(2002).
|
[19]
|
INTERACTION WITH HCV NS5A.
DOI=10.1128/JVI.76.18.9207-9217.2002; PubMed=12186904 [NCBI, ExPASy, EBI, Israel, Japan]
He Y.,
Nakao H.,
Tan S.-L.,
Polyak S.J.,
Neddermann P.,
Vijaysri S.,
Jacobs B.L.,
Katze M.G.;
"Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase.";
J. Virol. 76:9207-9217(2002).
|
[20]
|
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-607, AND MASS SPECTROMETRY.
TISSUE=Epithelium;
DOI=10.1074/mcp.M500089-MCP200; PubMed=15951569 [NCBI, ExPASy, EBI, Israel, Japan]
Zhang Y.,
Wolf-Yadlin A.,
Ross P.L.,
Pappin D.J.,
Rush J.,
Lauffenburger D.A.,
White F.M.;
"Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules.";
Mol. Cell. Proteomics 4:1240-1250(2005).
|
[21]
|
PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-452; TYR-467; TYR-556 AND TYR-580, AND MASS SPECTROMETRY.
TISSUE=Lung;
DOI=10.1016/j.cell.2007.11.025; PubMed=18083107 [NCBI, ExPASy, EBI, Israel, Japan]
Rikova K.,
Guo A.,
Zeng Q.,
Possemato A.,
Yu J.,
Haack H.,
Nardone J.,
Lee K.,
Reeves C.,
Li Y.,
Hu Y.,
Tan Z.,
Stokes M.,
Sullivan L.,
Mitchell J.,
Wetzel R.,
Macneill J.,
Ren J.M.,
Yuan J., ![]()
Bakalarski C.E.,
Villen J.,
Kornhauser J.M.,
Smith B.,
Li D.,
Zhou X.,
Gygi S.P.,
Gu T.-L.,
Polakiewicz R.D.,
Rush J.,
Comb M.J.;
"Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.";
Cell 131:1190-1203(2007).
|
[22]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 1-85.
DOI=10.1006/jmbi.1996.0190; PubMed=8648629 [NCBI, ExPASy, EBI, Israel, Japan]
Liang J.,
Chen J.K.,
Schreiber S.L.,
Clardy J.;
"Crystal structure of P13K SH3 domain at 2.0-A resolution.";
J. Mol. Biol. 257:632-643(1996).
|
[23]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 324-434.
DOI=10.1038/nsb0496-364; PubMed=8599763 [NCBI, ExPASy, EBI, Israel, Japan]
Nolte R.T.,
Eck M.J.,
Schlessinger J.,
Shoelson S.E.,
Harrison S.C.;
"Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes.";
Nat. Struct. Biol. 3:364-373(1996).
|
[24]
|
X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 115-298.
DOI=10.1073/pnas.93.25.14373; PubMed=8962058 [NCBI, ExPASy, EBI, Israel, Japan]
Musacchio A.,
Cantley L.C.,
Harrison S.C.;
"Crystal structure of the breakpoint cluster region-homology domain from phosphoinositide 3-kinase p85 alpha subunit.";
Proc. Natl. Acad. Sci. U.S.A. 93:14373-14378(1996).
|
[25]
|
X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 617-724 IN COMPLEX WITH PDGFRB.
DOI=10.1107/S0907444901012434; PubMed=11567151 [NCBI, ExPASy, EBI, Israel, Japan]
Pauptit R.A.,
Dennis C.A.,
Derbyshire D.J.,
Breeze A.L.,
Weston S.A.,
Rowsell S.,
Murshudov G.N.;
"NMR trial models: experiences with the colicin immunity protein Im7 and the p85alpha C-terminal SH2-peptide complex.";
Acta Crystallogr. D 57:1397-1404(2001).
|
[26]
|
STRUCTURE BY NMR OF 1-79.
DOI=10.1016/0092-8674(93)90582-B; PubMed=7681364 [NCBI, ExPASy, EBI, Israel, Japan]
Koyama S.,
Yu H.,
Dalgarno D.C.,
Shin T.B.,
Zydowsky L.D.,
Schreiber S.L.;
"Structure of the PI3K SH3 domain and analysis of the SH3 family.";
Cell 72:945-952(1993).
|
[27]
|
STRUCTURE BY NMR OF 91-104.
DOI=10.1021/bi9620969; PubMed=8961927 [NCBI, ExPASy, EBI, Israel, Japan]
Renzoni D.A.,
Pugh D.J.,
Siligardi G.,
Das P.,
Morton C.J.,
Rossi C.,
Waterfield M.D.,
Campbell I.D.,
Ladbury J.E.;
"Structural and thermodynamic characterization of the interaction of the SH3 domain from Fyn with the proline-rich binding site on the p85 subunit of PI3-kinase.";
Biochemistry 35:15646-15653(1996).
|
[28]
|
STRUCTURE BY NMR OF 617-724.
PubMed=8670861 [NCBI, ExPASy, EBI, Israel, Japan]
Breeze A.L.,
Kara B.V.,
Barratt D.G.,
Anderson M.,
Smith J.C.,
Luke R.W.,
Best J.R.,
Cartlidge S.A.;
"Structure of a specific peptide complex of the carboxy-terminal SH2 domain from the p85 alpha subunit of phosphatidylinositol 3-kinase.";
EMBO J. 15:3579-3589(1996).
|
[29]
|
VARIANT ILE-326.
PubMed=9032108 [NCBI, ExPASy, EBI, Israel, Japan]
Hansen T.,
Andersen C.B.,
Echwald S.M.,
Urhammer S.A.,
Clausen J.O.,
Vestergaard H.,
Owens D.,
Hansen L.,
Pedersen O.;
"Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index.";
Diabetes 46:494-501(1997).
|
[30]
|
VARIANT SEVERE INSULIN RESISTANCE GLN-409, AND VARIANT ILE-326.
DOI=10.1007/s001250050050; PubMed=10768093 [NCBI, ExPASy, EBI, Israel, Japan]
Baynes K.C.R.,
Beeton C.A.,
Panayotou G.,
Stein R.,
Soos M.,
Hansen T.,
Simpson H.,
O'Rahilly S.,
Shepherd P.R.,
Whitehead J.P.;
"Natural variants of human p85 alpha phosphoinositide 3-kinase in severe insulin resistance: a novel variant with impaired insulin-stimulated lipid kinase activity.";
Diabetologia 43:321-331(2000).
|
|
- FUNCTION: Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.
- SUBUNIT: Heterodimer of a p110 (catalytic) and a p85 (regulatory) subunits. Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3 (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV. Interacts with HCV NS5A. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST.
- INTERACTION:
Q9H222:ABCG5; NbExp=1; IntAct=EBI-79464, EBI-1761423;
P00519:ABL1; NbExp=1; IntAct=EBI-79464, EBI-375543;
P42684:ABL2; NbExp=1; IntAct=EBI-79464, EBI-1102694;
O43918:AIRE; NbExp=1; IntAct=EBI-79464, EBI-1753081;
Q9Y2D5:AKAP2; NbExp=1; IntAct=EBI-79464, EBI-1754555;
Q13023:AKAP6; NbExp=1; IntAct=EBI-79464, EBI-1056102;
Q96Q35:ALS2CR12; NbExp=1; IntAct=EBI-79464, EBI-1755548;
Q9BWW9:APOL5; NbExp=1; IntAct=EBI-79464, EBI-1753592;
O15085:ARHGEF11; NbExp=1; IntAct=EBI-79464, EBI-311099;
P38398:BRCA1; NbExp=1; IntAct=EBI-79464, EBI-349905;
O60885:BRD4; NbExp=1; IntAct=EBI-79464, EBI-723869;
Q9ULD4:BRPF3; NbExp=1; IntAct=EBI-79464, EBI-1753470;
P20810:CAST; NbExp=1; IntAct=EBI-79464, EBI-1268770;
P30260:CDC27; NbExp=1; IntAct=EBI-79464, EBI-994813;
Q13111:CHAF1A; NbExp=1; IntAct=EBI-79464, EBI-1020839;
Q14008:CKAP5; NbExp=1; IntAct=EBI-79464, EBI-310585;
Q8WX92:COBRA1; NbExp=1; IntAct=EBI-79464, EBI-347721;
Q9Y534:CSDC2; NbExp=1; IntAct=EBI-79464, EBI-1763657;
O75534:CSDE1; NbExp=1; IntAct=EBI-79464, EBI-719186;
P15509:CSF2RA; NbExp=1; IntAct=EBI-79464, EBI-1763264;
P98082:DAB2; NbExp=1; IntAct=EBI-79464, EBI-1171238;
Q14118:DAG1; NbExp=1; IntAct=EBI-79464, EBI-1755945;
P14868:DARS; NbExp=1; IntAct=EBI-79464, EBI-358730;
Q9ULH1:DDEF1; NbExp=1; IntAct=EBI-79464, EBI-346622;
O43150:DDEF2; NbExp=1; IntAct=EBI-79464, EBI-310968;
O14490:DLGAP1; NbExp=1; IntAct=EBI-79464, EBI-1753207;
Q9P1A6:DLGAP2; NbExp=1; IntAct=EBI-79464, EBI-1753397;
O95886:DLGAP3; NbExp=1; IntAct=EBI-79464, EBI-1752541;
Q9Y2H0:DLGAP4; NbExp=1; IntAct=EBI-79464, EBI-722139;
Q92988:DLX4; NbExp=1; IntAct=EBI-79464, EBI-1752755;
Q8IZD9:DOCK3; NbExp=1; IntAct=EBI-79464, EBI-1752361;
Q96EV8:DTNBP1; NbExp=1; IntAct=EBI-79464, EBI-465804;
Q9H1R2:DUSP15; NbExp=1; IntAct=EBI-79464, EBI-1752795;
Q9H8V3:ECT2; NbExp=1; IntAct=EBI-79464, EBI-1054039;
O43281:EFS; NbExp=1; IntAct=EBI-79464, EBI-718488;
P41970:ELK3; NbExp=1; IntAct=EBI-79464, EBI-1758534;
P11678:EPX; NbExp=1; IntAct=EBI-79464, EBI-1761505;
P21860:ERBB3; NbExp=3; IntAct=EBI-79464, EBI-720706;
O43909:EXTL3; NbExp=1; IntAct=EBI-79464, EBI-1754679;
O15360:FANCA; NbExp=1; IntAct=EBI-79464, EBI-81570;
P21333:FLNA; NbExp=1; IntAct=EBI-79464, EBI-350432;
O75369:FLNB; NbExp=1; IntAct=EBI-79464, EBI-352089;
Q14315:FLNC; NbExp=1; IntAct=EBI-79464, EBI-489954;
O75593:FOXH1; NbExp=1; IntAct=EBI-79464, EBI-1759806;
Q9QYY0:Gab1 (xeno); NbExp=1; IntAct=EBI-79464, EBI-644784;
Q9UBS5:GABBR1; NbExp=1; IntAct=EBI-79464, EBI-724156;
P34903:GABRA3; NbExp=1; IntAct=EBI-79464, EBI-1763805;
P10912:GHR; NbExp=1; IntAct=EBI-79464, EBI-286316;
Q9NZM4:GLTSCR1; NbExp=1; IntAct=EBI-79464, EBI-1754943;
Q9NQZ6:HCA127; NbExp=1; IntAct=EBI-79464, EBI-747993;
P08631:HCK; NbExp=1; IntAct=EBI-79464, EBI-346340;
P47928:ID4; NbExp=1; IntAct=EBI-79464, EBI-1754719;
O60674:JAK2; NbExp=1; IntAct=EBI-79464, EBI-518647;
Q9H1H9:KIF13A; NbExp=1; IntAct=EBI-79464, EBI-1759129;
P49916:LIG3; NbExp=1; IntAct=EBI-79464, EBI-1753381;
P27816:MAP4; NbExp=1; IntAct=EBI-79464, EBI-715255;
Q92918:MAP4K1; NbExp=1; IntAct=EBI-79464, EBI-881;
Q9NQ76:MEPE; NbExp=1; IntAct=EBI-79464, EBI-1753293;
Q15746:MYLK; NbExp=1; IntAct=EBI-79464, EBI-968482;
Q8NFW9:MYRIP; NbExp=1; IntAct=EBI-79464, EBI-1759414;
Q13285:NR5A1; NbExp=1; IntAct=EBI-79464, EBI-874629;
Q13087:PDIA2; NbExp=1; IntAct=EBI-79464, EBI-1752525;
P30086:PEBP1; NbExp=1; IntAct=EBI-79464, EBI-716384;
O75167:PHACTR2; NbExp=1; IntAct=EBI-79464, EBI-1754409;
O00750:PIK3C2B; NbExp=1; IntAct=EBI-79464, EBI-641107;
P32871:PIK3CA (xeno); NbExp=1; IntAct=EBI-79464, EBI-1373130;
P16885:PLCG2; NbExp=1; IntAct=EBI-79464, EBI-617403;
Q9H9Y6:POLR1B; NbExp=1; IntAct=EBI-79464, EBI-355441;
O75145:PPFIA3; NbExp=1; IntAct=EBI-79464, EBI-1763225;
P29074:PTPN4; NbExp=1; IntAct=EBI-79464, EBI-710431;
Q13905:RAPGEF1; NbExp=1; IntAct=EBI-79464, EBI-976876;
P26373:RPL13; NbExp=1; IntAct=EBI-79464, EBI-356849;
P10301:RRAS; NbExp=1; IntAct=EBI-79464, EBI-968703;
P13521:SCG2; NbExp=1; IntAct=EBI-79464, EBI-947132;
Q96B97:SH3KBP1; NbExp=1; IntAct=EBI-79464, EBI-346595;
Q9UPX8:SHANK2; NbExp=1; IntAct=EBI-79464, EBI-1570571;
Q9BYB0:SHANK3; NbExp=1; IntAct=EBI-79464, EBI-1752330;
Q9UHI7:SLC23A1; NbExp=1; IntAct=EBI-79464, EBI-1759386;
O60721:SLC24A1; NbExp=1; IntAct=EBI-79464, EBI-1753504;
Q15036:SNX17; NbExp=1; IntAct=EBI-79464, EBI-1752620;
Q9Y5X2:SNX8; NbExp=1; IntAct=EBI-79464, EBI-1752557;
Q07889:SOS1; NbExp=1; IntAct=EBI-79464, EBI-297487;
Q07890:SOS2; NbExp=1; IntAct=EBI-79464, EBI-298181;
Q96T58:SPEN; NbExp=1; IntAct=EBI-79464, EBI-765739;
Q9H5I1:SUV39H2; NbExp=1; IntAct=EBI-79464, EBI-723127;
O15056:SYNJ2; NbExp=1; IntAct=EBI-79464, EBI-310513;
O95455:TGDS; NbExp=1; IntAct=EBI-79464, EBI-1761487;
O43493:TGOLN2; NbExp=1; IntAct=EBI-79464, EBI-1752146;
P15157:TPSAB1; NbExp=1; IntAct=EBI-79464, EBI-1762849;
Q15661:TPSAB1; NbExp=1; IntAct=EBI-79464, EBI-1761369;
P20231:TPSB2; NbExp=1; IntAct=EBI-79464, EBI-1761383;
Q9ULW0:TPX2; NbExp=1; IntAct=EBI-79464, EBI-1037322;
Q9NRJ4:TULP4; NbExp=1; IntAct=EBI-79464, EBI-1753487;
Q96RL7:VPS13A; NbExp=1; IntAct=EBI-79464, EBI-1752583;
- ALTERNATIVE PRODUCTS:
4 named isoforms [FASTA] produced by alternative splicing.
| | |
| Name | 4 |
| Synonyms | p85I |
| Isoform ID | P27986-4 |
| Features which should be applied to build the isoform sequence: VSP_021845. |
|
|
- TISSUE SPECIFICITY: Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).
- DOMAIN: The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.
- PTM: Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.
- DISEASE: Defects in PIK3R1 are a cause of severe insulin resistance.
- SIMILARITY: Belongs to the PI3K p85 subunit family.
- SIMILARITY: Contains 1 Rho-GAP domain.
- SIMILARITY: Contains 2 SH2 domains.
- SIMILARITY: Contains 1 SH3 domain.
|
ExPASy Home page
